Arsenal Bio lays off 50% of its staff

And "frivolous" research under threat, despite strides in cancer treatments

September 19, 2025 Check out STAT+

Sponsored By

What's a three-letter word for a no-win situation? Solve it in the new STAT mini-crossword.

Adobe STAT+ | Arsenal Bio lays off 50% of its staff Until recently, Arsenal Bio had been one of the few cell therapy companies able to raise significant funds. By Jason Mast STAT+ | Amid industry headwinds, Biogen breaks ground on new headquarters The move ushers in the latest phase of Kendall Square's transformation into "the most innovative square mile on the planet." By Catherine Carlock — Boston Globe Despite fear of retaliation, hundreds of federal workers urge Congress to protect medicine and science Federal workers 'watching our agencies be dismantled from the inside' send letter of protest to Congress, say fear of retaliation kept many from signing on. By Angus Chen and Anil Oza Adobe STAT+ | FDA warning letters show how it intends to ratchet up pressure over drug ads The FDA's crackdown is unprecedented, but some experts questioned whether the agency has the staff to carry it out By Lizzy Lawrence and Ed Silverman

More around STAT

---

In case you missed it When "frivolous" research cures cancer, Politico. But research that seemed impractical has had an outsized impact on society. Aspirin can have "huge effect" in stopping colorectal cancer returning, major clinical trial finds, the Guardian. "The rug has been pulled out from under us": Cancer research funding turmoil leaves families scrambling, CNN

---

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Cancer Briefing? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser